Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Total Current Liabilities (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Total Current Liabilities for 3 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 57.4% to $14.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Dec 2025, up 57.4% year-over-year, with the annual reading at $14.0 million for FY2025, 57.4% up from the prior year.
  • Total Current Liabilities hit $14.0 million in Q4 2025 for Compass Therapeutics, up from $12.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $14.9 million in Q1 2025 to a low of $3.9 million in Q1 2024.
  • Historically, Total Current Liabilities has averaged $10.0 million across 3 years, with a median of $9.6 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: tumbled 65.21% in 2024 and later surged 282.74% in 2025.
  • Year by year, Total Current Liabilities stood at $7.8 million in 2023, then grew by 13.75% to $8.9 million in 2024, then surged by 57.4% to $14.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for CMPX at $14.0 million in Q4 2025, $12.4 million in Q3 2025, and $13.9 million in Q2 2025.